Oxaliplatin/5-FU chemotherapy without leucovorin in metastatic colorectal cancer

Abstract

Listen

Translate article

3734 Background: Oxaliplatin, 5-FU and leucovorin combination chemotherapy is one of effective regimen for metastatic colorectal cancer, even in patients who received 5-FU previously. But, in this regimen, the role of ( high dose) leucovorin in patients who previously received 5-FU and leucovorin is unknown. And the response rate of oxaliplatin/5-FU without leuconvorin given as the first regimen is almost similar to that of with leucovorin. We evaluated the effect of oxaliplatin and 5-FU without leucovorin in patients with metastatic colorectal cancer. Methods: Twenty four patients with metastatic colon(n=15), rectal (n=9) cancer were enrolled in this study. There were 9 male and 15 female patients and their median age was 63(range 37–74). Seventeen patients were received 5-FU and leucovorin previously. All patients received oxaliplatin 85mg/m2 on day 1 and, 5-FU bolus infusion 400mg/m2 on day 1 and continous infusion 600mg/m2/22hrs on days 1 and 2. The chemotherapy was repeated every 3 weeks. Response rate and toxicity were evaluated according to WHO criteria and NCI toxicity criteria respectively. Results: The median cycles of chemotherapy was 6(range1–9). Three were not evaluable. There were 6 partial responses with 25% response rate. In previously treated and untreated patients, the response rate were 23.5% (4/17) and 28.5%(2/7) respectively. The median survival time was 18 months(range 4–32). There was no grade III or IV toxicity except one grade 3 anemia. Conclusions: Oxaliplatin/5-FU combination chemotherapy without leucovorin showed good response and very tolerable toxicity. No significant financial relationships to disclose.